The organoids market size is expected to grow from US$ 3.03 billion in 2023 to US$ 15.01 billion by 2031; it is projected to register a CAGR of 18.2% during 2023-2031. The organoids market growth is attributed to the increasing demand for tumor modeling & biobanking, and a surging adoption of personalized drugs. However, the dearth of skilled professionals and stringent safety regulations hinder the growth of the market. Key developments by companies are likely to offer opportunities for market growth.

The organoids market has been segmented into the 5 major regions: North America, Europe, Asia Pacific, Middle East and Africa, South and Central America. North America dominates the organoids market. US held the major market share in the North America organoids market followed by Canada and Mexico.

In Canada, renal replacement procedures increased with an average rate of 1.4% per year from 2012 to 2021, as per the data published by the Canadian Institute for Health Information in January 2023. In the same period, organ donation and transplantation increased by 23%. A total of 2,750 transplantations occurred in 2021, while the count of organ donations was 1,328. The development of kidney organoids from human-induced pluripotent stem cells represents an essential advancement in regenerative medicine. They are expected to be used for disease modeling and drug discovery and might be applicable for organ transplantation. Moreover, several funds are allocated to research organizations to encourage the development of organoids. For instance, researchers at the University of Toronto received nearly US$ 27.31 million (CA$ 21 million) in funding from Medicine by Design during 2019-2021. Also, a US$ 148.3 million (CA$ 114 million) grant was provided to Medicine by Design as the Canada First Research Excellence Fund. Therefore, offering grants is a strategic initiative to catalyze transformative findings in regenerative medicine and accelerate them toward clinical impact through the convergence of engineering, medicine, and science. Market players are also focusing on organic growth strategies to strengthen their foothold. In April 2022, BC Children's Hospital Foundation launched new stem cell research technology at BC Children's Hospital. The hospital aims to combine and automate all aspects of stem cell culturing into a single piece of equipment at its Cellular and Regenerative Medicine Centre. Thus, the growing investment in the development of organoids is expected to fuel the organoids market in Canada over the forecast period.

By Application, Organoids Market-Based Insights

Based on application, the organoids market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023-2031. Developmental biology is the study of processes involved in the growth and development of multicellular organisms; these processes are predominantly controlled by their genes. Organoids developed from stem cells or tissues in culture can be transformed into structures that resemble the in-vivo anatomy and physiology of intact organs. Human organoid cultures can be used to study human development and model diseases with the same depth of analysis that is customary for research with nonhuman model organisms. With technological advancements, 3D bioprinting have been shown to possess massive potential to aid in organ development, as the time required for building organoids through 3D printing is much less than traditional tissue culture methods. Studies enabled by patient-derived human organoids may lead to new possibilities in the fields such as tissue engineering and regenerative medicine, generating knowledge and tools for preclinical testing in drug development studies.

The growth of the organoids market for developmental biology applications is attributed to the acceptance of organoids as the primary investigative research tool in human developmental biology. Moreover, organoids grown from embryonic stem cells offer a complete understanding of embryonic process development and insights into stem cell development.

Key players identified and evaluated while performing organoids market analysis are STEMCELL Technologies; Molecular Devices, LLC.; HUB Organoids B.V. (Hubrecht Organoid Technology); DefiniGEN; Organoid Therapeutics; Thermo Fisher Scientific Inc.; Corning Inc.; Merck KGaA; InSphero; ACRO Biosystems; and Bio-Techne Corporation.

In Nov-2022, ACROBiosystems developed a series of high-quality ActiveMax cytokines to support research on organoid cell culturing. The cytokines, including EGF, Noggin, R-Spondin 1, FGF10, FGF2, and Activin A, serve as growth factors for organoid culture and have been verified to promote organoid growth.

In Jul-2023, Molecular Devices, LLC expanded its organoid line services to support next-generation drug discovery by scaling up the production of standardized, assay-ready organoids, leveraging proprietary bioreactor and bioprocess technology.

In Feb-2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance

Investor Presentation, World Health Organization, National Institutes of Health, Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA), US Bureau of Labor Statistics, are a few of the major secondary sources referred to while preparing the report on the organoids market.